Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We utilise our cutting-edge, exclusive workflow to develop focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96P16
UPID:
RPR1A_HUMAN
Alternative names:
Cyclin-dependent kinase inhibitor 2B-related protein; p15INK4B-related protein
Alternative UPACC:
Q96P16; A8KA42; B2RBA3; Q7Z5G8; Q96FY9; Q9NVL4
Background:
Regulation of nuclear pre-mRNA domain-containing protein 1A, also known as Cyclin-dependent kinase inhibitor 2B-related protein or p15INK4B-related protein, plays a crucial role in cell cycle regulation. It interacts with the phosphorylated C-terminal heptapeptide repeat domain (CTD) of POLR2A and is involved in the dephosphorylation of the CTD by RPAP2. This protein acts as a negative regulator of cyclin-D1 (CCND1) and cyclin-E (CCNE1), key cyclins in cell cycle progression.
Therapeutic significance:
Understanding the role of Regulation of nuclear pre-mRNA domain-containing protein 1A could open doors to potential therapeutic strategies.